ADC Therapeutics SA financial data

Symbol
ADCT on NYSE
Industry
Pharmaceutical Preparations
Location
Biopole, Route De La Corniche 3 B, Epalinges, Switzerland
State of incorporation
Switzerland
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 514 %
Quick Ratio 24.8 %
Debt-to-equity -314 % -104%
Return On Equity 131 %
Return On Assets -61.3 %
Operating Margin -195 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 96.7M shares
Common Stock, Shares, Outstanding 96.7M shares
Entity Public Float 153M USD
Common Stock, Value, Issued 8.23M USD
Weighted Average Number of Shares Outstanding, Basic 105M shares +27.4%
Weighted Average Number of Shares Outstanding, Diluted 105M shares +27.4%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 70.7M USD +27.4%
Revenue from Contract with Customer, Excluding Assessed Tax 69.5M USD +26.3%
Research and Development Expense 113M USD -23.2%
Selling and Marketing Expense 46.7M USD -22.3%
General and Administrative Expense 43.6M USD -16.2%
Costs and Expenses 209M USD +6.69%
Operating Income (Loss) -138M USD +1.62%
Nonoperating Income (Expense) -26.8M USD +12.9%
Income Tax Expense (Benefit) 43.7M USD
Net Income (Loss) Attributable to Parent -212M USD +5.9%
Earnings Per Share, Basic -2.4 USD/shares +26.3%
Earnings Per Share, Diluted -2.4 USD/shares +26.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 274M USD
Inventory, Net 16.1M USD
Assets, Current 333M USD
Deferred Income Tax Assets, Net 0 USD -100%
Property, Plant and Equipment, Net 5.72M USD
Operating Lease, Right-of-Use Asset 9.19M USD
Other Assets, Noncurrent 1.17M USD
Assets 349M USD -25.2%
Accounts Payable, Current 14.4M USD
Accrued Liabilities, Current 53.3M USD
Liabilities, Current 67.7M USD
Deferred Income Tax Liabilities, Net 1.33M USD -66.7%
Operating Lease, Liability, Noncurrent 8.88M USD
Other Liabilities, Noncurrent 7.65M USD
Liabilities 521M USD -0.01%
Accumulated Other Comprehensive Income (Loss), Net of Tax 203K USD
Retained Earnings (Accumulated Deficit) -1.46B USD
Stockholders' Equity Attributable to Parent -172M USD -168%
Liabilities and Equity 349M USD

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -44.1M USD -186%
Net Cash Provided by (Used in) Financing Activities 356K USD -16.2%
Net Cash Provided by (Used in) Investing Activities -531K USD +47.7%
Common Stock, Shares, Issued 99.5M shares
Common Stock, Par or Stated Value Per Share 0.08 CHF/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 274M USD -11.6%
Interest Paid, Excluding Capitalized Interest, Operating Activities 3.9M USD +5.01%
Deferred Tax Assets, Valuation Allowance 212M USD +61.7%
Deferred Tax Assets, Gross 213M USD +23.9%
Operating Lease, Liability 11.6M USD
Depreciation 1.33M USD +6.33%
Payments to Acquire Property, Plant, and Equipment 531K USD -47.7%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -213M USD +7.57%
Lessee, Operating Lease, Liability, to be Paid 13.7M USD
Property, Plant and Equipment, Gross 11M USD
Operating Lease, Liability, Current 1.48M USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.94M USD
Lessee, Operating Lease, Liability, to be Paid, Year One 1.96M USD
Operating Lease, Weighted Average Discount Rate, Percent 0.04 pure +76.9%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 2.01M USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.98M USD
Deferred Tax Assets, Operating Loss Carryforwards 163M USD +24.2%
Unrecognized Tax Benefits 6.62M USD +27.6%
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.99M USD
Additional Paid in Capital 1.28B USD
Deferred Tax Assets, Net of Valuation Allowance 1.33M USD -96.8%
Interest Expense 51.2M USD +2.35%